Breaking News Instant updates and real-time market news.

BSX

Boston Scientific

$38.98

0.5 (1.30%)

08:39
10/02/18
10/02
08:39
10/02/18
08:39

Boston Scientific price target raised to $48 from $38 at Morgan Stanley

Morgan Stanley analyst David Lewis raised his price target on Boston Scientific shares to $48 from $38 as he believes the company's recent deal activity reflects an accelerating M&A climate, maturing venture portfolio and upcoming access to $2B in annual free cash flow and does not suggest a weakening of its core business. His deal by deal analysis suggests management's assumptions for the contributions from M&A appear conservative, added Lewis, who keeps an Overweight rating on Boston Scientific.

  • 09

    Oct

  • 24

    Oct

BSX Boston Scientific
$38.98

0.5 (1.30%)

09/04/18
09/04/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. UPS (UPS) upgraded to Strong Buy from Market Perform at Raymond James with analyst Patrick Tyler Brown saying he believes investors are underappreciating UPS' long-term Domestic EBIT and 2021 free cash flow outlook, which could be greater than $8B. 2. Qualcomm (QCOM) upgraded to Outperform from Neutral at Macquarie with analyst Srini Pajjuri saying he believes risk/reward is attractive and sees multiple catalysts ahead including a final settlement with Huawei in the near future, increasing probability of an Apple (AAPL) settlement, and a 5G cycle that is not fully reflected in consensus estimates. 3. Albemarle (ALB) upgraded to Buy from Hold at SunTrust with analyst James Sheehan saying investors have driven down the price of the stock amid lithium oversupply concern on incorrect assumption that it is a commodity. 4. Univar (UNVR) upgraded to Buy from Hold at Berenberg with analyst Thomas Burlton saying the company is improving its conversion margin and EBITDA growth while its cash generation is also getting better. 5. Boston Scientific (BSX) upgraded to Buy from Hold at Jefferies with analyst Raj Denhoy citing a survey of 25 U.S. transcatheter aortic valve replacement doctors to gauge interest in tBoston Scientific's Lotus value. While feedback was better for Edwards Lifesciences (EW) and Medtronic's (MDT) valves, the majority of respondents were still interested in trying Lotus and expected the valve to capture 16%-18% share of the market. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/05/18
ARGS
09/05/18
NO CHANGE
Target $41
ARGS
Buy
Boston Scientific price target raised to $41 from $36 at Argus
Argus analyst Jasper Hellweg raised his price target on Boston Scientific to $41 and kept his Buy rating, saying the company's outperformance over the past 3 months has been driven by its new product and acquisition news. Hellweg further cites the company's Q2 results showing organic sales growth up in all 3 of its sectors and across all regions. The analyst also notes that the stock price is trading in a bullish pattern of higher lows and highs going back to 2012 and believes that Boston Scientific is deserving of its premium valuation based on its growth outlook and profitability profile.
09/10/18
NEED
09/10/18
NO CHANGE
Target $43
NEED
Strong Buy
Boston Scientific price target raised to $43 from $39 at Needham
Needham analyst Mike Matson raised his price target on Boston Scientific to $43 and kept his Strong Buy rating. The analyst cites the company's latest $500M bid Augmenix, whose SpaceOAR reduces side effects associated with prostate radiotherapy. While the company expects "immaterial" earnings impact from the deal through 2019, Matson believes that it will strengthen its Urology & Pelvic Health business longer term, with added potential "revenue synergies given BSX's NxThera acquisition and legacy GreenLight XPS system".
09/28/18
JEFF
09/28/18
NO CHANGE
Target $300
JEFF
Buy
Jefferies boosts Teleflex, Boston Scientific targets after urologist survey
Jefferies analyst Raj Denhoy raised his estimates for Teleflex (TFX) and Boston Scientific (BSX) after conducting a survey of 50 U.S.-based urologists to better understand demand and utilization trends for Teleflex's recently acquired UroLift and Boston Scientific's recently acquired Rezum System. He found that UroLift is 15% of procedure mix and expected to reach 25% in two years, and that current mix for Rezum is 10% and expected to be 20% in two years. UroLift taking share from all other modalities including drug therapy while Rezum is gaining share from surgery/ablation, Denhoy tells investors in a research note. The analyst increased his price target for Teleflex to $300 and for Boston Scientific to $45. He keeps Buy rating on both stocks.

TODAY'S FREE FLY STORIES

CGC

Canopy Growth

$44.32

-0.67 (-1.49%)

13:14
02/22/19
02/22
13:14
02/22/19
13:14
Hot Stocks
Canopy reverses decline after CEO talks asset possibilities with Bloomberg »

Shares of Canopy Growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CGC

Canopy Growth

$44.31

-0.68 (-1.51%)

13:10
02/22/19
02/22
13:10
02/22/19
13:10
Periodicals
Canopy CEO tells Bloomberg company's assets could be spun into REIT »

Canopy Growth is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHGE

Baker Hughes

$26.29

0.01 (0.04%)

13:03
02/22/19
02/22
13:03
02/22/19
13:03
Hot Stocks
Baker Hughes reports U.S. rig count down 4 to 1,047 rigs »

Baker Hughes reports that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

  • 22

    May

  • 28

    May

EFX

Equifax

$110.23

-0.28 (-0.25%)

13:00
02/22/19
02/22
13:00
02/22/19
13:00
Hot Stocks
Equifax says U.S. regulators seek damages related to 2017 breach »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

BILI

Bilibili

$19.48

1.34 (7.39%)

13:00
02/22/19
02/22
13:00
02/22/19
13:00
Options
Bullish option flow in Bilibili as shares rally 7% ahead of earnings »

Bullish option flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

VALE

Vale

$12.45

0.43 (3.58%)

12:57
02/22/19
02/22
12:57
02/22/19
12:57
Periodicals
Federal prosecutors in Brazil seek arrest of senior Vale exec, Reuters reports »

Federal prosecutors in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KHC

Kraft Heinz

$34.99

-13.2 (-27.39%)

, K

Kellogg

$56.53

-1.8 (-3.09%)

12:57
02/22/19
02/22
12:57
02/22/19
12:57
Periodicals
Prescience Point sees Kellogg following Kraft Heinz with dividend cut »

Short seller Prescience…

KHC

Kraft Heinz

$34.99

-13.2 (-27.39%)

K

Kellogg

$56.53

-1.8 (-3.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 03

    Mar

SNAP

Snap

$9.74

0.35 (3.73%)

12:50
02/22/19
02/22
12:50
02/22/19
12:50
Options
Snap calls active as shares see strength »

Snap calls active as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

UBNK

United Financial

$16.11

0.02 (0.12%)

12:49
02/22/19
02/22
12:49
02/22/19
12:49
Hot Stocks
FJ Capital reports 6.47% passive stake in United Financial »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KPTI

Karyopharm

$7.49

-1.47 (-16.41%)

12:48
02/22/19
02/22
12:48
02/22/19
12:48
Hot Stocks
Karyopharm drops 40% after FDA posts Selinexor meeting briefing docs »

Shares of Karyopharm are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 06

    Apr

HK

Halcon Resources

$1.67

-0.12 (-6.70%)

12:47
02/22/19
02/22
12:47
02/22/19
12:47
Hot Stocks
Fir Tree comments on Halcon CEO departure, renews call for sale of company »

Fir Tree Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:45
02/22/19
02/22
12:45
02/22/19
12:45
General news
Breaking General news story  »

Week of 2/22 Baker-Hughes…

KPTI

Karyopharm

$8.97

0.01 (0.11%)

12:43
02/22/19
02/22
12:43
02/22/19
12:43
Hot Stocks
Breaking Hot Stocks news story on Karyopharm »

Karyopharm trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 06

    Apr

CMCSA

Comcast

$38.53

0.065 (0.17%)

, CMCSK

Comcast

$0.00

(0.00%)

12:43
02/22/19
02/22
12:43
02/22/19
12:43
On The Fly
Box Office Battle: 'How to Train Your Dragon' sequel flies into theaters »

Welcome to "Box Office…

CMCSA

Comcast

$38.53

0.065 (0.17%)

CMCSK

Comcast

$0.00

(0.00%)

FOX

21st Century Fox

$50.68

0.22 (0.44%)

FOXA

21st Century Fox

$50.97

0.23 (0.45%)

T

AT&T

$31.02

0.19 (0.62%)

DIS

Disney

$115.18

0.88 (0.77%)

LGF.A

Lionsgate

$15.49

0.15 (0.98%)

LGF.B

Lionsgate

$14.65

0.16 (1.10%)

SNE

Sony

$48.02

0.37 (0.78%)

VIA

Viacom

$34.75

(0.00%)

VIAB

Viacom

$29.44

0.25 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 27

    Feb

  • 03

    Mar

  • 04

    Mar

  • 04

    Mar

  • 07

    Mar

  • 11

    Mar

  • 11

    Mar

  • 11

    Mar

  • 20

    Mar

  • 06

    Jun

KPTI

Karyopharm

$9.03

0.07 (0.78%)

12:42
02/22/19
02/22
12:42
02/22/19
12:42
Hot Stocks
Breaking Hot Stocks news story on Karyopharm »

Karyopharm trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 06

    Apr

KPTI

Karyopharm

$9.03

0.07 (0.78%)

12:39
02/22/19
02/22
12:39
02/22/19
12:39
Hot Stocks
Breaking Hot Stocks news story on Karyopharm »

Karyopharm drops 16.5%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 06

    Apr

ATVI

Activision Blizzard

$41.62

-0.28 (-0.67%)

, TTWO

Take-Two

$86.50

-1.08 (-1.23%)

12:37
02/22/19
02/22
12:37
02/22/19
12:37
Periodicals
FTC plans public workshop to go over loot boxes in video games, Verge reports »

The Federal Trade…

ATVI

Activision Blizzard

$41.62

-0.28 (-0.67%)

TTWO

Take-Two

$86.50

-1.08 (-1.23%)

EA

Electronic Arts

$94.44

-2.39 (-2.47%)

UBSFY

Ubisoft

$0.00

(0.00%)

TCEHY

Tencent

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 12

    Mar

  • 13

    Mar

  • 21

    Mar

KPTI

Karyopharm

$9.03

0.07 (0.78%)

12:35
02/22/19
02/22
12:35
02/22/19
12:35
Hot Stocks
Karyopharm quickly drops 16.5% »

Shares of Karyopharm have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 06

    Apr

KPTI

Karyopharm

$9.04

0.08 (0.89%)

12:32
02/22/19
02/22
12:32
02/22/19
12:32
Hot Stocks
Breaking Hot Stocks news story on Karyopharm »

Karyopharm trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 06

    Apr

BIDU

Baidu

$166.90

-4.82 (-2.81%)

12:30
02/22/19
02/22
12:30
02/22/19
12:30
Options
10.1K Baidu Mar 170 - Sep 165 put spreads trade $7.20 after earnings »

10.1K Baidu Mar 170 - Sep…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

UBS

UBS

$12.38

0.055 (0.45%)

12:30
02/22/19
02/22
12:30
02/22/19
12:30
Periodicals
UBS ignored warnings in French tax case for years, Reuters says »

According to a written…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:30
02/22/19
02/22
12:30
02/22/19
12:30
General news
FX Action: USD-JPY »

FX Action: USD-JPY traded…

12:25
02/22/19
02/22
12:25
02/22/19
12:25
General news
Fed VC Clarida said the Fed should be "open minded" »

Fed VC Clarida said the…

GM

General Motors

$39.67

0.04 (0.10%)

12:23
02/22/19
02/22
12:23
02/22/19
12:23
Hot Stocks
GM says over 1,500 employees volunteered to transfer to other U.S. locations »

General Motors said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

GM

General Motors

$39.66

0.03 (0.08%)

12:21
02/22/19
02/22
12:21
02/22/19
12:21
Hot Stocks
GM extends production at Detroit/Hamtramck into January 2020 »

GM said it has notified…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.